Cowen analyst, Ken Cacciatore, reiterated his Outperform rating on shares of Otonomy (NASDAQ: OTIC) ahead of two Phase III trial ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE